therapy from those patients who are refractory to this treatment. [6] [7] [8] Bone marrow plasma cells are obtained by an invasive method of bone marrow biopsy, which is not useful in routine clinical practice. Therefore, Łuczak et al 4 have used proteomic analysis of se rum to overcome this obstacle. They used nano liquid chromatography-tandem mass spectrom etry to analyze digested serum protein samples from 61 proteasome inhibitor naive, transplant eligible patients with MM, who were resistant to the first line chemotherapy protocol CTD (cyclo phosphamide, thalidomide, and dexamethasone) and were scheduled for salvage PAD (bortezo mib, adriamycin [doxorubicin] , and dexameth asone) or VTD (bortezomib, thalidomide, and dexamethasone) chemotherapy. This analysis is an efficient method for identification of differ entially expressed proteins in serum from pa tients with MM.
Based on their response to therapy according to the International Myeloma Working Group cri teria, 9 Łuczak et al 4 classified patients with MM into 3 groups: CR/VGPR (24 patients), partial re sponse (PR; 19 patients), and stable or progres sive disease (SD/PD; 18 patients). A comparative proteomic analysis between these groups was per formed. A total of 16 upregulated and 35 down regulated proteins were identified in the sera of patients derived from the PD/SD group compared with the CR/VGPR group. The most highly corre lated differential protein was thyroxine binding globulin (TBG), which increased proportionally to response to bortezomib based therapy. A se vere acquired decrease in TBG levels was previ ously described in a patient with MM.
10 The hu man TBG gene was identified on chromosome Xq22.2 by fluorescence in situ hybridization. Little Plasma cell myeloma, or multiple myeloma (MM), is a clinically heterogeneous, incurable hemato logical malignancy of end stage B lineage cells. It accounts for approximately 1% to 2% of newly diagnosed cases of cancer worldwide.
1 The avail ability of novel therapies for the treatment of MM has a dramatic impact on the depth of re sponse to triplet therapies, particularly in re lapsed or refractory patients. 2, 3 The addition of proteasome inhibitors such as carfilzomib and ixazomib or the monoclonal antibodies such as the anti CS1 (also known as signaling lym phocytic activation molecule family member 7 [SLAMF7]), monoclonal antibody elotuzumab, or anti CD38 monoclonal antibody daratumumab to a treatment combination of lenalidomide and dexamethasone has been reported. Fewer results have been obtained with triplet therapies based on a combination of bortezomib and dexametha sone. The addition of the histone deacetylase in hibitor panobinostat or rolinostat or the mono clonal antibodies elotuzumab or daratumab has also been studied.
2,3
The study of Łuczak et al 4 
Apolipoprotein C 1 was also positively corre lated with the depth of response to bortezomib based therapy. On the other hand, quiescin sulf hydryl oxidase 1 (QSOX1) was found to be upreg ulated in the SP/PD group in comparison with the CR/VGP group. Protein stability, assembly, lo calization, and regulation depend on the forma tion of disulphide bonds between cysteine side chains. QSOX1 is an enzyme that oxidizes thiols during protein folding, reducing molecular oxy gen to hydrogen peroxide. Tumor cells may take advantage of oxidative environments at different stages of tumor progression. 11 However, there is some controversy as to whether QSOX1 is a mark er of poor or favorable outcome in breast cancer. 11 It may also have additional functions in tumors.
Complement components were found to be downregulated (C7 and C4) or upregulated (C9) in the PD/SD group in comparison with the CR/VGP group. The proteomic analysis in relation to C re active protein (CRP) showed the upregulation of this protein in the SP/PD group in comparison with the CR/VGP group. Validation studies of CRP levels were conducted using an enzyme linked immunosorbent assay to confirm the results of the proteomic analysis. The results obtained by both methods were found to be in agreement. CRP is a common marker of inflammation. CRP promoted proliferation of MM cells and protect ed MM cells from chemotherapy induced apop tosis.
12 CRP activates PI3K/Akt, ERK, and NF κB signaling pathways. 12 Identification of biomarkers allows the pre diction of therapy outcome with specific agents and may help avoid resistance. Further studies are needed to analyze and validate the role of proteins from the obtained proteomic signature.
